COVID-19 mortality in Europe, AstraZeneca and Pfizer homologous and heterologous immunisation, surgical leadership during COVID-19

Peer reviewed journals featured:
- Observational studies on:
  - COVID-19 mortality trends in Europe [here]
  - Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with AstraZeneca and Pfizer [here]
  - SARS-CoV-2 antigen rapid immunoassay in the emergency department [here]
- A case study on leadership as an effective human factor during COVID-19 [here]

Letters and correspondence discussed:
- Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 wave [here]
- The need for GP awareness about post-acute COVID-19 conditions [here]
- Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients [here]

Pre-peer review articles featured:
- Neutralisation of variants of concern, one year following COVID-19 infection and 1-2 months following vaccination [here]
- Saliva molecular testing for monitoring and diagnosing SARS-CoV-2 infection in children [here]

Guidance and reports
- The Therapeutic Goods Administration (TGA) weekly COVID-19 vaccine safety report [here]

News and blogs
- How vaccinated people spread Delta [here]
- Schools are not hubs of infection and are safe to reopen after the summer break in England [here]
- Australia’s COVID-19 experience [here]

Click here to subscribe to the daily evidence digest